Cargando…

Lipid-Lowering Therapy Utilization and Dosage Among Patients with Acute Coronary Syndrome Events: A Retrospective Cohort from 12 Community Hospitals

INTRODUCTION: Clinical practice guidelines recommend initiating a high-intensity LLT and continued monitoring of low-density lipoprotein cholesterol (LDL-C) following acute coronary syndrome (ACS). We used real-world data to describe LLT utilization after discharge and 1-year adherence. The reductio...

Descripción completa

Detalles Bibliográficos
Autores principales: Khatib, Rasha, Yeh, Eric J, Glowacki, Nicole, McGuiness, Catherine B, Xie, Handing, Wade, Rolin L, Kalich, Bethany A, Li, Yi, Rifai, Abdelhadi, Sawlani, Neal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166091/
https://www.ncbi.nlm.nih.gov/pubmed/37168051
http://dx.doi.org/10.2147/CLEP.S400903
_version_ 1785038373474271232
author Khatib, Rasha
Yeh, Eric J
Glowacki, Nicole
McGuiness, Catherine B
Xie, Handing
Wade, Rolin L
Kalich, Bethany A
Li, Yi
Rifai, Abdelhadi
Sawlani, Neal
author_facet Khatib, Rasha
Yeh, Eric J
Glowacki, Nicole
McGuiness, Catherine B
Xie, Handing
Wade, Rolin L
Kalich, Bethany A
Li, Yi
Rifai, Abdelhadi
Sawlani, Neal
author_sort Khatib, Rasha
collection PubMed
description INTRODUCTION: Clinical practice guidelines recommend initiating a high-intensity LLT and continued monitoring of low-density lipoprotein cholesterol (LDL-C) following acute coronary syndrome (ACS). We used real-world data to describe LLT utilization after discharge and 1-year adherence. The reduction in LDL-C was also evaluated. METHODS: Data were extracted from electronic health records (EHRs) from 12 hospitals in a large community healthcare system in midwestern United States between 2013 and 2019. Data on eligible patients recently discharged with an ACS event were linked to pharmacy claims data to describe LLT fill rates and 1-year post-discharge adherence. Adherence was reported as the proportion of days covered ≥80%. RESULTS: Of the 10,589 eligible patients, 49% filled a high-intensity statin at discharge and only 36% were adherent at 1 year. The mean (SD) age was 66.1±13.3, 39.3% were females, 58.8% were Caucasian, and 53.0% had Medicare. There was a clear trend for greater fill rates at discharge among patients with higher LDL-C values than those with lower values (p<0.01). Key predictors of high-intensity (versus medium-intensity) LLT use within 21 days after an ACS event included ACS type (odds ratio [OR] 0.59; 95% confidence interval [CI] 0.52–0.67 for NSTEMI versus STEMI), age group (OR: 0.59; 95% CI: 0.48–0.72 for >75 years versus <65 years), and statin use before index ACS event (OR: 1.56; 95% CI: 1.23–1.88). CONCLUSION: This real-world study found that despite recommendations in clinical practice guidelines, high-intensity LLT fill rates at discharge and 1-year adherence to LLT remain suboptimal. Clinical characteristics, including ACS type and LDL-C values, were strong predictors of filling and adherence to guideline-recommended therapy. Age, sex, and race/ethnicity disparities were observed in discharge fill rates and 1-year adherence. These results highlight the need for continued efforts at the patient and provider levels to improve LLT adherence among ACS patients.
format Online
Article
Text
id pubmed-10166091
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-101660912023-05-09 Lipid-Lowering Therapy Utilization and Dosage Among Patients with Acute Coronary Syndrome Events: A Retrospective Cohort from 12 Community Hospitals Khatib, Rasha Yeh, Eric J Glowacki, Nicole McGuiness, Catherine B Xie, Handing Wade, Rolin L Kalich, Bethany A Li, Yi Rifai, Abdelhadi Sawlani, Neal Clin Epidemiol Original Research INTRODUCTION: Clinical practice guidelines recommend initiating a high-intensity LLT and continued monitoring of low-density lipoprotein cholesterol (LDL-C) following acute coronary syndrome (ACS). We used real-world data to describe LLT utilization after discharge and 1-year adherence. The reduction in LDL-C was also evaluated. METHODS: Data were extracted from electronic health records (EHRs) from 12 hospitals in a large community healthcare system in midwestern United States between 2013 and 2019. Data on eligible patients recently discharged with an ACS event were linked to pharmacy claims data to describe LLT fill rates and 1-year post-discharge adherence. Adherence was reported as the proportion of days covered ≥80%. RESULTS: Of the 10,589 eligible patients, 49% filled a high-intensity statin at discharge and only 36% were adherent at 1 year. The mean (SD) age was 66.1±13.3, 39.3% were females, 58.8% were Caucasian, and 53.0% had Medicare. There was a clear trend for greater fill rates at discharge among patients with higher LDL-C values than those with lower values (p<0.01). Key predictors of high-intensity (versus medium-intensity) LLT use within 21 days after an ACS event included ACS type (odds ratio [OR] 0.59; 95% confidence interval [CI] 0.52–0.67 for NSTEMI versus STEMI), age group (OR: 0.59; 95% CI: 0.48–0.72 for >75 years versus <65 years), and statin use before index ACS event (OR: 1.56; 95% CI: 1.23–1.88). CONCLUSION: This real-world study found that despite recommendations in clinical practice guidelines, high-intensity LLT fill rates at discharge and 1-year adherence to LLT remain suboptimal. Clinical characteristics, including ACS type and LDL-C values, were strong predictors of filling and adherence to guideline-recommended therapy. Age, sex, and race/ethnicity disparities were observed in discharge fill rates and 1-year adherence. These results highlight the need for continued efforts at the patient and provider levels to improve LLT adherence among ACS patients. Dove 2023-05-04 /pmc/articles/PMC10166091/ /pubmed/37168051 http://dx.doi.org/10.2147/CLEP.S400903 Text en © 2023 Khatib et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Khatib, Rasha
Yeh, Eric J
Glowacki, Nicole
McGuiness, Catherine B
Xie, Handing
Wade, Rolin L
Kalich, Bethany A
Li, Yi
Rifai, Abdelhadi
Sawlani, Neal
Lipid-Lowering Therapy Utilization and Dosage Among Patients with Acute Coronary Syndrome Events: A Retrospective Cohort from 12 Community Hospitals
title Lipid-Lowering Therapy Utilization and Dosage Among Patients with Acute Coronary Syndrome Events: A Retrospective Cohort from 12 Community Hospitals
title_full Lipid-Lowering Therapy Utilization and Dosage Among Patients with Acute Coronary Syndrome Events: A Retrospective Cohort from 12 Community Hospitals
title_fullStr Lipid-Lowering Therapy Utilization and Dosage Among Patients with Acute Coronary Syndrome Events: A Retrospective Cohort from 12 Community Hospitals
title_full_unstemmed Lipid-Lowering Therapy Utilization and Dosage Among Patients with Acute Coronary Syndrome Events: A Retrospective Cohort from 12 Community Hospitals
title_short Lipid-Lowering Therapy Utilization and Dosage Among Patients with Acute Coronary Syndrome Events: A Retrospective Cohort from 12 Community Hospitals
title_sort lipid-lowering therapy utilization and dosage among patients with acute coronary syndrome events: a retrospective cohort from 12 community hospitals
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166091/
https://www.ncbi.nlm.nih.gov/pubmed/37168051
http://dx.doi.org/10.2147/CLEP.S400903
work_keys_str_mv AT khatibrasha lipidloweringtherapyutilizationanddosageamongpatientswithacutecoronarysyndromeeventsaretrospectivecohortfrom12communityhospitals
AT yehericj lipidloweringtherapyutilizationanddosageamongpatientswithacutecoronarysyndromeeventsaretrospectivecohortfrom12communityhospitals
AT glowackinicole lipidloweringtherapyutilizationanddosageamongpatientswithacutecoronarysyndromeeventsaretrospectivecohortfrom12communityhospitals
AT mcguinesscatherineb lipidloweringtherapyutilizationanddosageamongpatientswithacutecoronarysyndromeeventsaretrospectivecohortfrom12communityhospitals
AT xiehanding lipidloweringtherapyutilizationanddosageamongpatientswithacutecoronarysyndromeeventsaretrospectivecohortfrom12communityhospitals
AT waderolinl lipidloweringtherapyutilizationanddosageamongpatientswithacutecoronarysyndromeeventsaretrospectivecohortfrom12communityhospitals
AT kalichbethanya lipidloweringtherapyutilizationanddosageamongpatientswithacutecoronarysyndromeeventsaretrospectivecohortfrom12communityhospitals
AT liyi lipidloweringtherapyutilizationanddosageamongpatientswithacutecoronarysyndromeeventsaretrospectivecohortfrom12communityhospitals
AT rifaiabdelhadi lipidloweringtherapyutilizationanddosageamongpatientswithacutecoronarysyndromeeventsaretrospectivecohortfrom12communityhospitals
AT sawlanineal lipidloweringtherapyutilizationanddosageamongpatientswithacutecoronarysyndromeeventsaretrospectivecohortfrom12communityhospitals